These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
648 related articles for article (PubMed ID: 16513225)
1. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Goodman LB; Wagner B; Flaminio MJ; Sussman KH; Metzger SM; Holland R; Osterrieder N Vaccine; 2006 Apr; 24(17):3636-45. PubMed ID: 16513225 [TBL] [Abstract][Full Text] [Related]
2. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus. Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066 [TBL] [Abstract][Full Text] [Related]
3. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215 [TBL] [Abstract][Full Text] [Related]
4. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205 [TBL] [Abstract][Full Text] [Related]
5. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075 [TBL] [Abstract][Full Text] [Related]
6. The equine immune response to equine herpesvirus-1: the virus and its vaccines. Kydd JH; Townsend HG; Hannant D Vet Immunol Immunopathol; 2006 May; 111(1-2):15-30. PubMed ID: 16476492 [TBL] [Abstract][Full Text] [Related]
7. Serological responses and clinical outcome after vaccination of mares and foals with equine herpesvirus type 1 and 4 (EHV-1 and EHV-4) vaccines. Bresgen C; Lämmer M; Wagner B; Osterrieder N; Damiani AM Vet Microbiol; 2012 Nov; 160(1-2):9-16. PubMed ID: 22633483 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95). Heldens JG; Pouwels HG; van Loon AA Vet J; 2004 Mar; 167(2):150-7. PubMed ID: 14975389 [TBL] [Abstract][Full Text] [Related]
9. Comparison of protective efficacies between intranasal and intramuscular vaccination of horses with a modified live equine herpesvirus type-1 vaccine. Bannai H; Nemoto M; Tsujimura K; Yamanaka T; Kokado H; Kondo T; Matsumura T Vet Microbiol; 2018 Aug; 222():18-24. PubMed ID: 30080668 [TBL] [Abstract][Full Text] [Related]
10. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals. Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474 [TBL] [Abstract][Full Text] [Related]
11. The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Breathnach CC; Yeargan MR; Sheoran AS; Allen GP Equine Vet J; 2001 Nov; 33(7):651-7. PubMed ID: 11770985 [TBL] [Abstract][Full Text] [Related]
12. Equine herpesvirus type 1 modified live virus vaccines: quo vaditis? Rosas CT; Goodman LB; von Einem J; Osterrieder N Expert Rev Vaccines; 2006 Feb; 5(1):119-31. PubMed ID: 16451114 [TBL] [Abstract][Full Text] [Related]
13. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV). Rosas CT; Tischer BK; Perkins GA; Wagner B; Goodman LB; Osterrieder N Virus Res; 2007 Apr; 125(1):69-78. PubMed ID: 17241683 [TBL] [Abstract][Full Text] [Related]
14. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus. Holmes MA; Townsend HG; Kohler AK; Hussey S; Breathnach C; Barnett C; Holland R; Lunn DP Vet Immunol Immunopathol; 2006 May; 111(1-2):67-80. PubMed ID: 16476488 [TBL] [Abstract][Full Text] [Related]
15. Control of EHV-1 viremia and nasal shedding by commercial vaccines. Goehring LS; Wagner B; Bigbie R; Hussey SB; Rao S; Morley PS; Lunn DP Vaccine; 2010 Jul; 28(32):5203-11. PubMed ID: 20538091 [TBL] [Abstract][Full Text] [Related]
16. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease. Schnabel CL; Babasyan S; Rollins A; Freer H; Wimer CL; Perkins GA; Raza F; Osterrieder N; Wagner B J Virol; 2019 Nov; 93(22):. PubMed ID: 31462575 [TBL] [Abstract][Full Text] [Related]
17. Cellular and antibody responses to equine herpesviruses 1 and 4 following vaccination of horses with modified-live and inactivated viruses. Ellis JA; Bogdan JR; Kanara EW; Morley PS; Haines DM J Am Vet Med Assoc; 1995 Mar; 206(6):823-32. PubMed ID: 7538990 [TBL] [Abstract][Full Text] [Related]
18. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges. Patel JR; Földi J; Bateman H; Williams J; Didlick S; Stark R Vet Microbiol; 2003 Mar; 92(1-2):1-17. PubMed ID: 12488066 [TBL] [Abstract][Full Text] [Related]
19. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus). Fitzpatrick DR; Studdert MJ Am J Vet Res; 1984 Oct; 45(10):1947-52. PubMed ID: 6208822 [TBL] [Abstract][Full Text] [Related]
20. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1. Foote CE; Raidal SL; Pecenpetelovska G; Wellington JE; Whalley JM Vet Immunol Immunopathol; 2006 May; 111(1-2):97-108. PubMed ID: 16504306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]